MCID: VLV011
MIFTS: 49

Vulvovaginal Candidiasis

Categories: Infectious diseases, Skin diseases, Reproductive diseases

Aliases & Classifications for Vulvovaginal Candidiasis

MalaCards integrated aliases for Vulvovaginal Candidiasis:

Name: Vulvovaginal Candidiasis 12 3 14
Candidiasis, Vulvovaginal 42 69
Candidiasis of Vulva and Vagina 12
Candidal Vulvovaginitis Nos 12
Candidiasis Vulvovaginal 52
Candidal Vulvovaginitis 12
Monilial Vulvovaginitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2272
ICD10 33 B37.3
ICD9CM 35 112.1
MeSH 42 D002181
NCIt 47 C2914
UMLS 69 C0700345

Summaries for Vulvovaginal Candidiasis

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a “vaginal yeast infection.” Other names for this infection are “vaginal candidiasis,” “vulvovaginal candidiasis,” or “candidal vaginitis.”

MalaCards based summary : Vulvovaginal Candidiasis, also known as candidiasis, vulvovaginal, is related to candidiasis and vulvovaginitis. An important gene associated with Vulvovaginal Candidiasis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and Influenza A. The drugs Miconazole and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and colon, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge.

Related Diseases for Vulvovaginal Candidiasis

Diseases related to Vulvovaginal Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
id Related Disease Score Top Affiliating Genes
1 candidiasis 11.1
2 vulvovaginitis 11.1
3 imperforate oropharynx-costo vetebral anomalies 10.7 CD79A MBL2
4 gonococcal synovitis 10.7 CLEC7A MBL2
5 b cell linker protein deficiency 10.7 CD79A MBL2
6 vaginitis 10.6
7 basilar artery occlusion 10.6 CD79A DEFB4A
8 bullous retinoschisis 10.6 CD79A DEFB4A
9 hemangioma of orbit 10.6 CD79A IL2
10 fallopian tube carcinoma 10.6 CD79A IL2
11 bowman's membrane folds or rupture 10.5 DEFB1 DEFB4A
12 bladder diverticulum 10.5 CD79A CLEC7A
13 malignant renovascular hypertension 10.5 CD79A IFNG
14 walker dyson syndrome 10.5 MBL2 NLRP3
15 clear cell adenocarcinoma of ovary 10.5 DEFB1 DEFB4A
16 dumping syndrome 10.5 CD79A IFNG
17 cholesteatoma of middle ear 10.5 CD79A IFNG
18 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 10.5 CD79A IFNG
19 chronic erythremia 10.4 CD79A DEFB1
20 cutaneous candidiasis 10.4 IFNG MBL2
21 mycobacterium kansasii 10.4 CLEC7A NLRP3
22 diabetic angiopathy 10.4 CD79A IL4
23 aniseikonia 10.4 CD79A IL4
24 polyneuropathy due to drug 10.4 CD79A IL4
25 bulbospinal polio 10.4 IFNG IL2
26 cutaneous ganglioneuroma 10.4 CD79A IL4
27 autoimmune polyglandular syndrome type 3 10.4 IFNG IL2
28 anthracosilicosis 10.4 IFNG IL2
29 graft-versus-host disease, protection against 10.4 IFNG IL2
30 hypoparathyroidism, x-linked 10.4 CD79A IL4
31 apple allergy 10.4 CD79A IL4
32 ectropion 10.3 CLEC7A IL4
33 sclerosing cholangitis 10.3 DEFB1 DEFB4A
34 periventricular leukomalacia 10.3 DEFB4A IFNG
35 phlyctenulosis 10.3 IL4 MBL2
36 amyotrophic lateral sclerosis type 10 10.3 IFNG IL2
37 philophthalmiasis 10.3 CD79A IL4
38 bacterial vaginosis 10.3
39 parametritis 10.3 IFNG IL2
40 foodborne botulism 10.3 CD79A IL2
41 chronic graft versus host disease 10.3 IFNG IL2
42 alkhurma hemorrhagic fever 10.3 CLEC7A IL4
43 visual snow syndrome 10.3 IL2 IL4
44 inappropriate adh syndrome 10.3 CD79A DEFB1 DEFB4A
45 barbiturate dependence 10.2 CD79A DEFB4A IL2
46 cyclosporiasis 10.2 IFNG IL2
47 pmm2-congenital disorder of glycosylation 10.2 IL2 IL4
48 myoclonic astatic epilepsy 10.2 IFNG IL4
49 dioctophymiasis 10.2 IL2 IL4
50 eye accommodation disease 10.2 IFNG IL4

Comorbidity relations with Vulvovaginal Candidiasis via Phenotypic Disease Network (PDN): (show all 12)


Acute Cystitis Anxiety Disorder
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Oral Candidiasis
Osteoporosis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Vulvovaginal Candidiasis:



Diseases related to Vulvovaginal Candidiasis

Symptoms & Phenotypes for Vulvovaginal Candidiasis

MGI Mouse Phenotypes related to Vulvovaginal Candidiasis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.92 CD79A CLEC7A F2 IFNG IL2 IL4
2 homeostasis/metabolism MP:0005376 9.86 IL4 MBL2 NLRP3 CD79A CLEC7A F2
3 digestive/alimentary MP:0005381 9.85 CLEC7A F2 IFNG IL2 IL4 NLRP3
4 immune system MP:0005387 9.76 CD79A CLEC7A F2 IFNG IL2 IL4
5 liver/biliary system MP:0005370 9.35 CD79A IFNG IL2 IL4 NLRP3
6 renal/urinary system MP:0005367 9.02 CD79A IFNG IL4 MBL2 NLRP3

Drugs & Therapeutics for Vulvovaginal Candidiasis

Drugs for Vulvovaginal Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
2
Fluconazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 86386-73-4 3365
3
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 18323-44-9 29029
4
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 23593-75-1 2812
5
Dequalinium Approved Phase 4 6707-58-0
6
Terconazole Approved Phase 4,Early Phase 1 67915-31-5 441383
7
Metronidazole Approved Phase 4,Phase 3,Phase 2,Early Phase 1 443-48-1 4173
8
Ephedrine Approved Phase 4 299-42-3 9294
9
Pseudoephedrine Approved Phase 4 90-82-4 7028
10 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Clindamycin palmitate Phase 4,Phase 3,Early Phase 1
19 Clindamycin phosphate Phase 4,Phase 3,Early Phase 1
20 Anti-Infective Agents, Local Phase 4,Phase 3
21 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
22 Immune Sera Phase 4
23 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Early Phase 1
24 Antibiotics, Antitubercular Phase 4,Phase 3
25 Antitubercular Agents Phase 4,Phase 3
26 Tetrahydrozoline Phase 4,Phase 3
27 Autonomic Agents Phase 4
28 Nasal Decongestants Phase 4
29 Ophthalmic Solutions Phase 4
30 Peripheral Nervous System Agents Phase 4
31 Pharmaceutical Solutions Phase 4
32 Respiratory System Agents Phase 4
33 Vasoconstrictor Agents Phase 4
34
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 14956 5280965
35
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576 3823
36
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
37
Azithromycin Approved Phase 3 83905-01-5 55185 53477736 447043
38
Rifabutin Approved Phase 3 72559-06-9 6323490
39
Tinidazole Approved, Investigational Phase 3 19387-91-8 5479
40 Antiparasitic Agents Phase 3,Phase 2,Early Phase 1
41 Antiprotozoal Agents Phase 3,Phase 2,Early Phase 1
42 Liposomal amphotericin B Phase 3,Phase 2
43 Alkylating Agents Phase 3
44
Aluminum hydroxide Approved Phase 1, Phase 2 21645-51-2
45 Titanium dioxide Approved Phase 2 13463-67-7
46 Adjuvants, Immunologic Phase 1, Phase 2
47 Antacids Phase 1, Phase 2
48 Anti-Ulcer Agents Phase 1, Phase 2
49 Gastrointestinal Agents Phase 1, Phase 2
50 Vaccines Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 55)

id Name Status NCT ID Phase Drugs
1 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
2 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
3 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
4 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
5 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
6 Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
7 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Recruiting NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
8 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
9 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole
10 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
11 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
12 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
13 A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients Completed NCT00002122 Phase 3 Azithromycin;Rifabutin;Fluconazole
14 Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
15 ProF-001_Phase IIa Recruiting NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
16 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Not yet recruiting NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
17 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Not yet recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
18 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
19 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
20 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
21 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
22 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2 VT-1161 (oral);Fluconazole (oral)
23 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
24 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
25 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2 CD101 gel (3%);CD101 gel (1%);CD101 ointment (6%);CD101 ointment (1%);Fluconazole
26 TOL-463 Phase 2 Study for Vaginitis Completed NCT02866227 Phase 2 TOL-463;TOL-463
27 Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis Completed NCT00635622 Phase 2 LACTIN-V;Placebo control substance
28 An Active-Controlled, Dose-Finding Study of SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Recruiting NCT03253094 Phase 2 Fluconazole;SCY-078
29 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Active, not recruiting NCT02267382 Phase 2 VT-1161;Placebo
30 Patients With Vulvovaginal Candidiasis Not yet recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
31 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Not yet recruiting NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
32 Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
33 Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection Completed NCT01067131 Phase 1
34 Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463 Completed NCT01812889 Phase 1 TOL-463 Vaginal ovule;TOL-463 Vaginal gel
35 Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Completed NCT02730494 Phase 1
36 Will Vaginal Colonization of Lactobacillus Increase Cure Rate After Treatment of Bacterial Vaginosis and Chronic Vulvovaginal Candida Unknown status NCT02295579
37 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis Completed NCT00803738 Terconazole Vaginal Suppository;Terazol Vaginal Suppository
38 Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) Completed NCT00895453 itraconazole;lactobacillus gasseri;classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
39 A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations Completed NCT01039584 Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream
40 Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization Completed NCT02888197
41 Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis Completed NCT02203942
42 Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Completed NCT02150655 Early Phase 1
43 Observational Program Neo-Penotran® Forte Completed NCT01335373 Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
44 A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients Completed NCT00002438 Itraconazole
45 Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network Completed NCT00503542 Early Phase 1 Terazol or oral fluconazole for candidal vaginitis;Metronidazole or Clindamycin for Bacterial Vaginosis;Flagyl for definitively diagnosed vaginal trichomoniasis
46 Epidemiological Study in Subjects With Vulvovaginal Candidiases Recruiting NCT03064789
47 Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis Recruiting NCT02859493
48 Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women Recruiting NCT01915251
49 Oral Probiotics for the Treatment and Prevention of Vulvovaginal Infections in Pregnancy - Double-blind, Randomized, Placebo-controlled Study Recruiting NCT02795845
50 Women's Improvement of Sexual Health (WISH) Demonstration Project Active, not recruiting NCT03045809

Search NIH Clinical Center for Vulvovaginal Candidiasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: candidiasis, vulvovaginal

Genetic Tests for Vulvovaginal Candidiasis

Anatomical Context for Vulvovaginal Candidiasis

MalaCards organs/tissues related to Vulvovaginal Candidiasis:

39
Skin, Testes, Colon, Neutrophil, B Cells

Publications for Vulvovaginal Candidiasis

Articles related to Vulvovaginal Candidiasis:

(show top 50) (show all 389)
id Title Authors Year
1
Recurrent vulvovaginal candidiasis. ( 28615397 )
2017
2
Molecular Identification and Antifungal Susceptibility Pattern of Non-albicans Candida Species Isolated from Vulvovaginal Candidiasis ( 28688376 )
2017
3
Contribution of TLR2 pathway in the pathogenesis of vulvovaginal candidiasis. ( 28911197 )
2017
4
Recurrent vulvovaginal candidiasis. ( 28927765 )
2017
5
Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital. ( 28511380 )
2017
6
Characterization of virulence factors of vaginal and anal isolates of Candida albicans sequentially obtained from patients with vulvovaginal candidiasis in north-east Brazil. ( 28844452 )
2017
7
Vulvovaginal candidiasis: Etiology, symptomatology and risk factors. ( 28314677 )
2017
8
Emergence of Candida glabrata in vulvovaginal candidiasis should be attributed to selective pressure or virulence ability? ( 28730269 )
2017
9
Automatic diagnosis of vulvovaginal candidiasis from Pap smear images. ( 28419509 )
2017
10
Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen? ( 28868834 )
2017
11
Prevalence of Candida albicans, Candida dubliniensis and Candida africana in pregnant women suffering from vulvovaginal candidiasis in Argentina. ( 28385421 )
2017
12
Elevated nitric oxide in recurrent vulvovaginal candidiasis - association to clinical findings. ( 28052314 )
2017
13
Prevalence of vulvovaginal candidiasis in pregnancy at three health centers in Burkina Faso. ( 28939305 )
2017
14
Vaginal Candida spp. genomes from women with vulvovaginal candidiasis. ( 28582496 )
2017
15
Effectiveness of Ageratina pichinchensis Extract in Patients with Vulvovaginal Candidiasis. A Randomized, Double-Blind, and Controlled Pilot Study. ( 28299831 )
2017
16
Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvovaginal candidiasis: A random clinical trial. ( 28760590 )
2017
17
Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study. ( 28066940 )
2017
18
Recurrent vulvovaginal candidiasis: A review of guideline recommendations. ( 28299777 )
2017
19
Efficacy of Histatin5 in a murine model of vulvovaginal candidiasis caused by Candida albicans. ( 28645176 )
2017
20
Prevalence of Candida africana and Candida dubliniensis, in vulvovaginal candidiasis: First Turkish Candida africana isolates from vulvovaginal candidiasis. ( 28641919 )
2017
21
Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole. ( 28696240 )
2017
22
Is human Dectin-1 Y238X gene polymorphism related to susceptibility to recurrent vulvovaginal candidiasis? ( 28681024 )
2016
23
ALS1 and ALS3 gene expression and biofilm formation in Candida albicans isolated from vulvovaginal candidiasis. ( 27376044 )
2016
24
Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis. ( 27915337 )
2016
25
Chronic vulvovaginal candidiasis in patients using a levonorgestrel-containing intrauterine device. ( 27957732 )
2016
26
Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis. ( 27129474 )
2016
27
Quality of life in patients with chronic vulvovaginal candidiasis: A before and after study on the impact of oral fluconazole therapy. ( 27170259 )
2016
28
The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. ( 27073145 )
2016
29
Syngonanthus nitens Bong. (Rhul.)-Loaded Nanostructured System for Vulvovaginal Candidiasis Treatment. ( 27556451 )
2016
30
The Effects of Ozonated Olive Oil and Clotrimazole Cream for Treatment of Vulvovaginal Candidiasis. ( 27548492 )
2016
31
Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus. ( 27298383 )
2016
32
Antifungal effects of Lavandula binaludensis and Cuminum cyminum essential oils against Candida albicans strains isolated from patients with recurrent vulvovaginal candidiasis. ( 27751723 )
2016
33
Microsatellite analysis of genotype distribution patterns of Candida albicans vulvovaginal candidiasis in Nanjing, China and its association with pregnancy, age and clinical presentation. ( 26861467 )
2016
34
Candida nivariensis as a New Emergent Agent of Vulvovaginal Candidiasis: Description of Cases and Review of Published Studies. ( 26708316 )
2016
35
Vulvovaginal Candidiasis in Pregnant Women and its Importance for Candida Colonization of Newborns. ( 27552787 )
2016
36
Candida duobushaemulonii: an emerging rare pathogenic yeast isolated from recurrent vulvovaginal candidiasis in Brazil. ( 27304096 )
2016
37
Genotyping and Persistence of Candida albicans from Pregnant Women with Vulvovaginal Candidiasis. ( 27882525 )
2016
38
A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana. ( 27838642 )
2016
39
Management of chronic vulvovaginal candidiasis: a long term retrospective study. ( 27250078 )
2016
40
Highlights Regarding Host Predisposing Factors to Recurrent Vulvovaginal Candidiasis: Chronic Stress and Reduced Antioxidant Capacity. ( 27415762 )
2016
41
Comparing the Recurrence of Vulvovaginal Candidiasis in Patients Undergoing Prophylactic Treatment with Probiotic and Placebo During the 6A Months. ( 27206514 )
2016
42
Transcriptomic Analysis of Vulvovaginal Candidiasis Identifies a Role for the NLRP3 Inflammasome. ( 25900651 )
2015
43
Miconazole Nitrate Vaginal Suppository 1,200 mg versus Oral Fluconazole 150 mg in Treating Severe Vulvovaginal Candidiasis. ( 25720546 )
2015
44
Phospholipase and Aspartyl Proteinase Activities of Candida Species Causing Vulvovaginal Candidiasis in Patients with Type 2 Diabetes Mellitus. ( 26032358 )
2015
45
A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis. ( 25877666 )
2015
46
Antifungal susceptibility and molecular typing of 115 Candida albicans isolates obtained from vulvovaginal candidiasis patients in 3 Shanghai maternity hospitals. ( 26468549 )
2015
47
Molecular Characterization of Highly Susceptible Candida africana from Vulvovaginal Candidiasis. ( 26183965 )
2015
48
Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. ( 26690853 )
2015
49
Case Report Dynamical evaluation of vaginal micro-ecosystem in a Chinese woman with recurrent vulvovaginal candidiasis. ( 25867410 )
2015
50
Neutrophil Gelatinase-Associated Lipocalin Concentration in Vaginal Fluid: Relation to Bacterial Vaginosis and Vulvovaginal Candidiasis. ( 25670719 )
2015

Variations for Vulvovaginal Candidiasis

Expression for Vulvovaginal Candidiasis

Search GEO for disease gene expression data for Vulvovaginal Candidiasis.

Pathways for Vulvovaginal Candidiasis

Pathways related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 CD79A CLEC7A DEFB1 DEFB4A IFNG IL2
2
Show member pathways
12.55 IFNG IL2 IL4 NLRP3
3
Show member pathways
12.39 CD79A IFNG IL2 IL4
4 12.29 CD79A IFNG IL2 IL4
5
Show member pathways
12.11 DEFB4A IFNG IL4
6
Show member pathways
11.99 IFNG IL2 IL4
7
Show member pathways
11.96 DEFB4A IFNG IL4
8
Show member pathways
11.93 IFNG IL2 IL4
9 11.78 IFNG IL2 IL4
10
Show member pathways
11.74 IFNG IL2 IL4
11 11.57 IFNG IL2 IL4
12 11.54 IFNG IL2 IL4
13
Show member pathways
11.49 IFNG IL2 IL4
14 11.25 IFNG IL2 IL4
15
Show member pathways
11.21 IFNG IL2
16 11.1 IFNG IL4
17 11.03 IFNG IL2
18 11.02 IFNG IL2 IL4
19 10.99 CD79A IFNG IL2 IL4
20 10.91 IFNG IL2 IL4
21 10.75 IFNG IL2 IL4
22 10.53 F2 IFNG NLRP3

GO Terms for Vulvovaginal Candidiasis

Cellular components related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 DEFB1 DEFB4A F2 IFNG IL2 IL4
2 external side of plasma membrane GO:0009897 9.46 CD79A F2 IFNG IL4
3 Golgi lumen GO:0005796 9.43 DEFB1 DEFB4A F2
4 extracellular region GO:0005576 9.23 DEFB1 DEFB4A F2 IFNG IL2 IL4

Biological processes related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.9 F2 IFNG IL2 IL4
2 innate immune response GO:0045087 9.88 CLEC7A DEFB1 MBL2 NLRP3
3 adaptive immune response GO:0002250 9.79 CD79A IFNG IL2
4 chemotaxis GO:0006935 9.75 DEFB1 DEFB4A IL4
5 defense response GO:0006952 9.73 DEFB1 DEFB4A NLRP3
6 immune response GO:0006955 9.72 DEFB1 DEFB4A IFNG IL2 IL4
7 defense response to bacterium GO:0042742 9.71 DEFB1 DEFB4A IFNG MBL2
8 defense response to Gram-positive bacterium GO:0050830 9.7 DEFB1 DEFB4A MBL2
9 immune system process GO:0002376 9.65 CD79A CLEC7A IL2 MBL2 NLRP3
10 acute-phase response GO:0006953 9.63 F2 MBL2
11 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.63 IL2 IL4
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 IFNG IL2 IL4
13 B cell activation GO:0042113 9.62 CD79A IL4
14 positive regulation of activated T cell proliferation GO:0042104 9.61 IL2 IL4
15 positive regulation of interleukin-1 beta secretion GO:0050718 9.61 IFNG NLRP3
16 positive regulation of T cell proliferation GO:0042102 9.61 IFNG IL2 IL4
17 innate immune response in mucosa GO:0002227 9.59 DEFB1 IL4
18 positive regulation of T cell differentiation GO:0045582 9.57 IL2 IL4
19 negative regulation of growth of symbiont in host GO:0044130 9.55 IFNG MBL2
20 positive regulation of chemokine biosynthetic process GO:0045080 9.54 IFNG IL4
21 negative regulation of acute inflammatory response GO:0002674 9.51 IL4 NLRP3
22 positive regulation of interleukin-13 production GO:0032736 9.49 IL4 NLRP3
23 positive regulation of MHC class II biosynthetic process GO:0045348 9.48 IFNG IL4
24 positive regulation of protein phosphorylation GO:0001934 9.46 F2 IFNG IL2 IL4
25 negative regulation of T-helper 17 cell differentiation GO:2000320 9.37 IL2 IL4
26 defense response to protozoan GO:0042832 9.13 CLEC7A IFNG IL4
27 positive regulation of isotype switching to IgG isotypes GO:0048304 8.8 IFNG IL2 IL4

Molecular functions related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.43 CLEC7A IL2 MBL2
2 cytokine activity GO:0005125 9.33 IFNG IL2 IL4
3 growth factor activity GO:0008083 9.13 F2 IL2 IL4
4 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB1 DEFB4A

Sources for Vulvovaginal Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....